What's your COVID-19 investment strategy? Defensive stocks offer safety, growth
Focus shift to strategies that consider a recovery in business and economic activity
ZAWYA - 15 Apr 2020
Dallah Healthcare Company (4004.SE)
Also known as: DHC, Dallah Health
54.00 SAR 1.001.89%
DHC Stock Price & Performance
Recommendation
-
Div Yield
-
P/E (Last 12 Month)
28.75
Upside
-
Target Price (Mean)
-
Open
52.90 SAR
Previous Close
54.00 SAR
Turnover
12.55M SAR
EPS
2.032 SAR
Volume
233,915
Transactions
780
Market Cap
3.85B SAR
IPO Date
16-Dec-2012
Analyst Estimates
| EPS | Revenue | |
|---|---|---|
| Mean Estimate |  | |
| Smart Estimate | | |
| Predicted Surprise | | |
| Mean Chg % | | |
Starmine Models
StarMine provides a suite of proprietary alpha-generating analytics and models spanning sectors, regions, and markets.
| Bullish | |
|---|---|
| Value Momentum | |
| Intrinsic Valuation | |
| Relative Valuation | |
| Credit Risk - Smart Ratios | |
| Credit Risk- Text Mining | |
| Bearish | |
|---|---|
| Price Momentum | |
About Dallah Healthcare Company
Business Summary
Ownership and operation of general hospitals. Through its main subsidiaries, manufacture of branded drugs; distribution of pharmaceuticals; offers hospital and medical center maintenance services.
Country of Incorporation
Ownership Type
Established In
1994
Primary Sector
Stock Listing
| ID | Stock Type | Currency | Exchange | Symbol |
|---|---|---|---|---|
| 4004.SSE | Ordinary | SAR | Saudi SE | 4004 |
Contact details
Primary address
Al Nakheel TowerKing Fahad Road 1157
2nd Floor
Al Nakheel Area
87833
Saudi Arabia
Riyadh
12381
CONTACT
- Tel: +966 11-299-5555
- Tel: +966 11-225-5065
- Tel: +966 11-225-5769
- Fax: +966 11-470-2748
- Fax: +966 11-225-0602
- Fax: +966 11-455-0803
- Email: www.dallahhealth.com
Region
RiyadhOwnership
Ownership
| Investor | Holding | No. of Shares | Last Update |
|---|---|---|---|
| | | |
| | | |
Holding Concentrations
| Investor | Holding | No. of Shares | Last Update |
|---|---|---|---|
| | | |
| | | |
Financials
Revenue
Net Income
Profit Margin
Total Assets
Total Liabilities
Debt to Assets
Operating
Investing
Financing
Executives
Dr Ahmad Bin Saleh Mohammed Babaeer
Chief Executive Officer and Managing Director
Mr Khalid Mohammed Ali Al Saudi
Chief Financial Officer
Dr Salah Rashed Al Faqih
Chief of Medical Staff
Board Members
Mr Tariq Othman Abdullah Al Qusabi
Chairman
Mr Mohieddine Saleh Abdullah Kamel
Vice Chairman
Dr Mohammed Rashed Mohammed Al Fagih
Director
Company information provided by Refinitiv
Refinitiv research team update company information from primary sources (company annual reports, press releases, company websites, corporate briefings, official statements/interviews) and reliable secondary sources (stock markets, reliable third party publications).
Tuesday Outlook: Asian stocks advance; gold near record high as virus risks remain
Dollar's August bounce retraces slightly; oil gives up gains on expected output increase
Stock Market Data
Powered By Knowledge Direct